Rituximab for connective tissue disease-associated interstitial lung disease

Lancet Respir Med. 2023 Jan;11(1):3-4. doi: 10.1016/S2213-2600(22)00356-3. Epub 2022 Nov 11.

Authors

Andreina Manfredi¹, Carlo Salvarani¹, Marco Sebastiani²

Affiliations

¹ Rheumatology Unit, University of Modena and Reggio Emilia, Azienda Policlinico of Modena, Modena, Italy.
² Rheumatology Unit, University of Modena and Reggio Emilia, Azienda Policlinico of Modena, Modena, Italy. Electronic address: marco.sebastiani@unimore.it.

PMID: 36375480
DOI: 10.1016/S2213-2600(22)00356-3

No abstract available

Publication types

Comment

MeSH terms

Connective Tissue Diseases* / complications
Connective Tissue Diseases* / drug therapy
Humans
Lung
Lung Diseases, Interstitial* / drug therapy
Lung Diseases, Interstitial* / etiology
Rituximab / therapeutic use

Substances

Rituximab